RPS4XP22

Across TCGA pan-cancer cohorts, RPS4XP22 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RPS4XP22’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPS4XP22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPS4XP22 is over-expressed in tumor, although a few such as BRCA and UCEC show the opposite, repressed pattern.

KIRC, CHOL, and BRCA are the cancer types where RPS4XP22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS4XP22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.486	.003	5	view →
CHOL	All	II,III,IV	+2.720	.016	4	view →
BRCA	Female	All	−0.382	.006	4	view →
UCEC	All	All	−1.150	.001	2	view →
THCA	All	IV	+0.910	.036	1	view →
COAD	Female	IV	+0.585	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RPS4XP22–KIRC

Open the KIRC breakdown →